Bristol Myers Squibb Company $BMY Stock Position Reduced by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 0.5% during the second quarter, HoldingsChannel.com reports. The firm owned 154,644 shares of the biopharmaceutical company’s stock after selling 746 shares during the period. Bristol Myers Squibb makes up about 1.1% of John G Ullman & Associates Inc.’s portfolio, making the stock its 27th largest holding. John G Ullman & Associates Inc.’s holdings in Bristol Myers Squibb were worth $7,158,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BMY. Wellington Management Group LLP grew its position in Bristol Myers Squibb by 297.0% in the first quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock worth $1,447,198,000 after acquiring an additional 17,750,938 shares in the last quarter. GQG Partners LLC grew its position in Bristol Myers Squibb by 22,647.6% in the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock worth $733,310,000 after acquiring an additional 11,970,598 shares in the last quarter. Nuveen LLC bought a new stake in Bristol Myers Squibb in the first quarter worth approximately $624,369,000. Kingstone Capital Partners Texas LLC bought a new stake in Bristol Myers Squibb in the second quarter worth approximately $98,898,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Bristol Myers Squibb by 8.6% in the first quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company’s stock worth $1,638,501,000 after buying an additional 2,131,205 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $57.23.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $43.63 on Friday. The stock has a market cap of $88.80 billion, a P/E ratio of 17.59, a PEG ratio of 2.26 and a beta of 0.33. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The company has a fifty day moving average price of $46.07 and a 200 day moving average price of $47.47. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the prior year, the company earned $2.07 EPS. The business’s quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. Bristol Myers Squibb’s dividend payout ratio is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.